Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Clinical Trial Results
Biotech
Bright Minds anti-seizure candidate shines in phase 2 win
The New York-based biotech’s serotonin mimic BMB-101 significantly reduced the number of seizures in patients with absence seizures and epilepsies.
Darren Incorvaia
Jan 6, 2026 10:38am
Galapagos' last immunology asset posts mixed results
Dec 19, 2025 6:05am
Nektar claims ph. 2 alopecia success after excluding 4 patients
Dec 16, 2025 5:05pm
Aviceda eye disease hopeful fails to top Astellas med in phase 2
Dec 15, 2025 2:14pm
ASH: Novartis details ianalumab's phase 3 rare blood disease win
Dec 9, 2025 7:30am
Merck mulls PV program’s future while Takeda takes victory lap
Dec 8, 2025 4:30pm
